Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.

Humans Temozolomide / pharmacology Glioblastoma / drug therapy Retrospective Studies Antineoplastic Agents, Alkylating / pharmacology Brain Neoplasms / drug therapy DNA Methylation DNA Repair Enzymes / metabolism High-Throughput Nucleotide Sequencing DNA / therapeutic use
CpG site glioblastoma pyrosequencing volumetric analysis

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
26 Sep 2022
Historique:
received: 20 08 2022
revised: 18 09 2022
accepted: 24 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

The aim of the present study was to determine which individual or combined CpG sites among O

Identifiants

DOI: 10.3390/biom12101379 PMID: 36291588 PMC: PMC9599060
pubmed: 36291588
pii: biom12101379
doi: 10.3390/biom12101379
pmc: PMC9599060
pii:
doi:

Substances chimiques

Temozolomide YF1K15M17Y
Antineoplastic Agents, Alkylating 0
DNA Repair Enzymes EC 6.5.1.-
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184
pubmed: 28574607
Neuro Oncol. 2009 Aug;11(4):348-56
pubmed: 19224763
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Transl Med. 2012 Mar 06;10:36
pubmed: 22390413
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Int J Biol Markers. 2015 May 26;30(2):e208-16
pubmed: 25588856
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Neuro Oncol. 2021 Sep 1;23(9):1457-1469
pubmed: 34467991
J Mol Diagn. 2007 Jul;9(3):368-81
pubmed: 17591937
J Neurooncol. 2022 May;157(3):561-571
pubmed: 35397757
CNS Neurosci Ther. 2019 Mar;25(3):314-322
pubmed: 30117294
Int J Cancer. 2012 Sep 1;131(5):1104-13
pubmed: 22020830
J Neurooncol. 2017 May;133(1):193-201
pubmed: 28516344
Acta Neuropathol. 2011 May;121(5):651-61
pubmed: 21287394
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Mod Pathol. 2019 Jan;32(1):4-15
pubmed: 30291347
J Neurooncol. 2014 Feb;116(3):487-96
pubmed: 24420923
Brain Tumor Pathol. 2015 Jan;32(1):22-30
pubmed: 24748374

Auteurs

Tomohiro Hosoya (T)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Masamichi Takahashi (M)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
ORCID: 0000-0001-8792-1993

Calvin Davey (C)

Humanome Laboratory, 2-4-10 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Jun Sese (J)

Humanome Laboratory, 2-4-10 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Mai Honda-Kitahara (M)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yasuji Miyakita (Y)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Makoto Ohno (M)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
ORCID: 0000-0001-8031-4306

Shunsuke Yanagisawa (S)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Takaki Omura (T)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Daisuke Kawauchi (D)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yukie Ozeki (Y)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Miyu Kikuchi (M)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Tomoyuki Nakano (T)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Akihiko Yoshida (A)

Department of Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Hiroshi Igaki (H)

Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Yuko Matsushita (Y)

Department of Brain Disease Translational Research, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Koichi Ichimura (K)

Department of Brain Disease Translational Research, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Yoshitaka Narita (Y)

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
ORCID: 0000-0003-4303-6006

Articles similaires

Comprehensive comparative analysis and development of molecular markers for Lasianthus species based on complete chloroplast genome sequences.

Yue Zhang, Meifang Song, Deying Tang et al.
1.00
Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Imidazoles › Dacarbazine › Témozolomide › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Agents alcoylants › Antinéoplasiques alcoylants › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Phénomènes génétiques › Méthylation de l'ADN › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Enzymes de réparation de l'ADN › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de séquence › Séquençage nucléotidique à haut débit › Volumetric Analysis of Glioblastoma for...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › Volumetric Analysis of Glioblastoma for...